1.19
-0.015(-1.25%)
Currency In EUR
Address
400, Boulevard Gonthier d’Andernach
Illkirch-Graffenstaden, 67405
France
Phone
33 3 88 27 91 00
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
144
First IPO Date
November 05, 2008
| Name | Title | Pay | Year Born |
| Dr. Alessandro Riva M.D. | Chief Executive Officer & Chairman of the Board | 840,000 | 1960 |
| Mr. James Wentworth M.B.A., Ph.D. | Vice President & Chief Business Officer | 0 | 1980 |
| Ms. Lucie Larguier | Vice President & Chief Financial Officer | 0 | 1984 |
| Dr. Simone Silva Steiner Ph.D. | Chief Technical Officer | 0 | 1976 |
| Dr. Maurizio Ceppi | Vice President & Chief Scientific Officer | 0 | 1972 |
| Mr. John Felitti J.D., LLM | Vice President, General Counsel & Corporate Secretary | 0 | 1970 |
| Ms. Gaelle Stadtler | Vice President & Director of Human Resources | 0 | 1984 |
| Ms. Christelle Schwoerer | Chief Human Resources Officer | 0 | 1992 |
| Ms. Emmanuelle Dochy M.D. | Vice President of Medical Affairs & Chief Medical Officer | 0 | 1976 |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
